NAD + levels decline during ageing, and alterations in NAD + homeostasis can be found in virtually all age-related diseases, including neurodegeneration, diabetes and cancer
Access the complete GLP-1 Pipeline Update table for November 2025
Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial
Cukierman-Yaffe T, Gerstein HC, Colhoun HM, Diaz R, Garca-Prez L-E, Lakshmanan M, et al
Because this effect is entirely glucose-dependent, insulin secretion decreases as plasma glucose approaches normal levels, providing a significant safety advantage over traditional secretagogues